全文获取类型
收费全文 | 1487347篇 |
免费 | 111000篇 |
国内免费 | 2862篇 |
专业分类
耳鼻咽喉 | 20684篇 |
儿科学 | 49751篇 |
妇产科学 | 38830篇 |
基础医学 | 208198篇 |
口腔科学 | 37627篇 |
临床医学 | 132753篇 |
内科学 | 301270篇 |
皮肤病学 | 30851篇 |
神经病学 | 121744篇 |
特种医学 | 60323篇 |
外国民族医学 | 673篇 |
外科学 | 228959篇 |
综合类 | 29311篇 |
现状与发展 | 2篇 |
一般理论 | 543篇 |
预防医学 | 110588篇 |
眼科学 | 32948篇 |
药学 | 108600篇 |
3篇 | |
中国医学 | 2716篇 |
肿瘤学 | 84835篇 |
出版年
2021年 | 12603篇 |
2019年 | 13437篇 |
2018年 | 18428篇 |
2017年 | 13849篇 |
2016年 | 15163篇 |
2015年 | 17391篇 |
2014年 | 24468篇 |
2013年 | 36219篇 |
2012年 | 51142篇 |
2011年 | 53931篇 |
2010年 | 31739篇 |
2009年 | 30152篇 |
2008年 | 50707篇 |
2007年 | 54058篇 |
2006年 | 53970篇 |
2005年 | 52700篇 |
2004年 | 51083篇 |
2003年 | 48729篇 |
2002年 | 47531篇 |
2001年 | 65737篇 |
2000年 | 67810篇 |
1999年 | 58198篇 |
1998年 | 17602篇 |
1997年 | 15737篇 |
1996年 | 15925篇 |
1995年 | 15034篇 |
1994年 | 14141篇 |
1993年 | 13150篇 |
1992年 | 45434篇 |
1991年 | 44296篇 |
1990年 | 42923篇 |
1989年 | 40780篇 |
1988年 | 37500篇 |
1987年 | 36764篇 |
1986年 | 34196篇 |
1985年 | 32891篇 |
1984年 | 24972篇 |
1983年 | 20990篇 |
1982年 | 12659篇 |
1981年 | 11565篇 |
1979年 | 21777篇 |
1978年 | 15292篇 |
1977年 | 12943篇 |
1976年 | 12079篇 |
1975年 | 12906篇 |
1974年 | 14944篇 |
1973年 | 14362篇 |
1972年 | 13105篇 |
1971年 | 11872篇 |
1970年 | 11153篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
71.
P Avalos-Peralta† A Herrera† JJ Ríos-Martín‡ AM Pérez-Bernal† D Moreno-Ramírez† F Camacho† 《Journal of the European Academy of Dermatology and Venereology》2006,20(1):79-83
We report the case of a patient with a 13-year history of pemphigus vulgaris (PV) treated with immunosuppressive agents, prednisone and mycophenolate mofetil who had developed lesions of Kaposi's sarcoma (KS) on a sole plaque of PV that had been previously treated with intralesional injections of steroids. The lesions were surgically removed and polymerase chain reaction (PCR) demonstrated human herpesvirus-8 (HHV-8) DNA. There were neither recurrences nor later dissemination of KS following gradual decrease of the immunosuppressive therapy. We suggest that the treatment with intralesional steroids may have influenced the local reactivation of a latent infection of the virus, determining the appearance of this localized KS. 相似文献
72.
73.
74.
Claudia Gedlicka Gudrun Hager Martina Weissenböck Wilhelm Gedlicka Birgit Knerer Johannes Kornfehl Michael Formanek 《Journal of oral pathology & medicine》2006,35(8):472-478
BACKGROUND: 1Alpha,25-dihydroxyvitamin D(3) [1,25(OH)(2) Vitamin D(3)] induces growth inhibition in squamous cell carcinoma (SCC) cell lines of the head and neck by arresting the cells in the G0/G1 phase of the cell cycle, probably due to an enhanced expression of p21, which could be demonstrated in other cell lines (JPPA, SCC9) before. In SCC25, a SCC cell line isolated from tongue, growth inhibition but no overexpression of p21 was detected. The retinoblastoma gene, as a direct target of G1 cyclin-CDK complexes, showed an obvious shift from the hyperphosphorylated to the hypophosphorylated form under 1,25(OH)(2)Vitamin D(3), which indicates that the growth inhibition takes place in the G0/G1 phase. To explore the possible pathway of growth inhibition in SCC25 we investigated other cell cycle inhibitors (p18, p19, p27). METHODS: Synchronized cells were treated with 1,25(OH)(2)Vitamin D(3) over 96 h. The cell cycle status and expression of cell cycle-regulating proteins was determined by fluorescence-activated cell sorting (FACS) and Western blotting. An overexpression of p18 in 1,25(OH)(2)Vitamin D(3) vs. ethanol-treated cells was determined until 30 h in SCC25. No influence was detectable on the expression of p27 and p19. CONCLUSION: One mechanism by which 1,25(OH)(2)Vitamin D(3) controls cell growth might be the upregulation of p21. As p21 was unsusceptible to 1,25(OH)(2)Vitamin D(3) in SCC25, other inhibiting proteins were necessary to be tested. The proven upregulation of p18 seems to be the responsible step for growth inhibition of 1,25(OH)(2)Vitamin D(3) in SCC25. 相似文献
75.
Andrea R Genazzani Hermann P G Schneider Nick Panay Esme A Nijland 《Gynecological endocrinology》2006,22(7):369-375
OBJECTIVES: To identify and describe current women's thoughts about the menopause, hormone treatment (HT) and perceptions about breast cancer. METHODS: Between December 2004 and January 2005, 4201 postmenopausal women in seven European countries were interviewed via a standardized computer-aided telephone interview protocol. RESULTS: Almost all women reported to have experienced climacteric symptoms, and 63% of the women rated them as being severe. Only 52% of women were aware of the benefits of HT for relief of climacteric symptoms. Although 84% felt that severe symptoms should be treated, only 40% had used HT at some point in time. Thirty-four percent of the women preferring treatment with natural products did so because of the risk of breast cancer associated with HT. HT was recognized by 59% of the women as one of the most important contributors to an increased breast cancer risk. Most women received their information about HT and breast cancer risk from the media. CONCLUSIONS: This European survey reveals that the majority of women experience climacteric symptoms but that their decision whether or not to use HT is highly dependent on their concern about breast cancer risk. An increase in knowledge of the benefits and risks of HT is required for women to make appropriate decisions about hormone use. 相似文献
76.
77.
78.
79.
Conclusions Limitation of this analysis is participation of limited centers. Though all the regions of the country are represented total
number of procedures reported are less. Isolated CABG is commonest procedure performed in 2004. Congenital surgical procedures
are more than the valvular heart disease procedure. For appropriate categorization we need standard nomenclature for various
congenital surgical procedures. 相似文献
80.